Razi Cov Pars

Razi Cov Pars is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute Razi Cov Pars is a covid-19 vaccine based on recombinant protein, which is being produced by Razi Vaccine and Serum Research Institute, Iran. This vaccine is the first injectable-intranasal recombinant protein corona vaccine. It's the second Iranian COVID-19 vaccine reaching human trials and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine.

Medical uses

It requires three doses given day 0, day 21 and day 51.

Pharmacology

Razi Cov Pars is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein.

Manufacturing

It's planned to produce one million doses of the vaccine each month as of September 2021.
As of 25 November 2021, 5 millions doses have been delivered to the Iranian Ministry of Health.